Search

Your search keyword '"Griesinger, Frank"' showing total 91 results

Search Constraints

Start Over You searched for: Author "Griesinger, Frank" Remove constraint Author: "Griesinger, Frank" Search Limiters Full Text Remove constraint Search Limiters: Full Text Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
91 results on '"Griesinger, Frank"'

Search Results

1. Evolutionary trajectories of small cell lung cancer under therapy

2. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

6. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

7. Community-driven development of a modified progression-free survival ratio for precision oncology

8. Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy.

9. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

14. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)

15. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

16. Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.

17. Decision Conflicts in Clinical Care during COVID-19: A Multi-Perspective Inquiry.

18. Differences in Stakeholders' Perception of the Impact of COVID-19 on Clinical Care and Decision-Making.

19. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.

21. Decision Conflicts in Clinical Care during COVID-19: A Patient Perspective.

23. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia

28. Afatinib as first-line treatment in patients with EGFR -mutated non-small cell lung cancer in routine clinical practice.

29. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia

30. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer.

31. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.

32. Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC.

33. Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol

35. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.

36. I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.

37. Radiation and Dose‐densification of R‐CHOP in Primary Mediastinal B‐cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial.

38. Radiation and Dose‐densification of R‐CHOP in Aggressive B‐cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.

41. Beyond Mere Application Structure Thoughts on the Future of Cloud Orchestration Tools.

42. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

43. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

44. The potassium channel Ether go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia.

45. Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol.

46. Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy.

47. Intrinsic B lymphocyte defect in untreated patients with Hodgkin's disease.

48. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.

Catalog

Books, media, physical & digital resources